NEWS | BEAM Alliance

NEWS

Madam Therapeutics closes first financing round to develop novel antibiotics against drug resistant bacteria

Madam Therapeutics closes first financing round to develop novel antibiotics against drug resistant bacteria

Madam Therapeutics, a privately-held biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, today announced the closing of its first financing round of 1,1M EUR.

Full PR available here